GIPR and obesity due to melanocortin 4 receptor deficiency: In conclusion, this study characterises the metabolic effects of GIPR agonist and antagonist administration in both lean and HFD‐induced mice, providing novel insights highly relevant to the personalisation of obesity treatments.